FocalTherics’ (FOCL) Buy Rating Reaffirmed at HC Wainwright

FocalTherics (NASDAQ:FOCL)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 139.23% from the company’s previous close.

FOCL has been the subject of several other reports. Mizuho set a $15.00 price target on FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 price target on shares of FocalTherics in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, FocalTherics presently has a consensus rating of “Hold” and a consensus price target of $7.75.

FocalTherics Stock Up 1.2%

Shares of FOCL opened at $4.18 on Tuesday. The firm has a market cap of $156.88 million, a price-to-earnings ratio of -4.06 and a beta of -0.04. The company has a fifty day moving average of $5.34. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.38 and a current ratio of 1.60.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The firm had revenue of $13.20 million for the quarter. As a group, equities research analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Ryan Rhodes bought 21,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $99,750.00. Following the completion of the transaction, the chief executive officer directly owned 626,649 shares of the company’s stock, valued at approximately $2,976,582.75. This represents a 3.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joshua Levine bought 10,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $47,500.00. Following the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $213,750. This represents a 28.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 116,000 shares of company stock valued at $551,000 over the last ninety days. Insiders own 10.10% of the company’s stock.

Institutional Trading of FocalTherics

Large investors have recently bought and sold shares of the company. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics during the first quarter worth $38,000. Lido Advisors LLC acquired a new stake in FocalTherics during the 1st quarter valued at $40,000. Kovack Advisors Inc. acquired a new stake in FocalTherics during the 4th quarter valued at $53,000. Leonteq Securities AG purchased a new stake in FocalTherics during the 4th quarter worth $313,000. Finally, Flax Pond Capital LLC acquired a new position in FocalTherics in the 4th quarter worth $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.